Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study

Florian Kurth, Michel Develoux, Matthieu Mechain, Jan Clerinx, Spinello Antinori, Ida E. Gjørup, Joaquím Gascon, Kristine Mørch, Emanuele Nicastri, Michael Ramharter, Alessandro Bartoloni, Leo Visser, Thierry Rolling, Philipp Zanger, Guido Calleri, Joaquín Salas-Coronas, Henrik Nielsen, Gudrun Just-Nübling, Andreas Neumayr, Anna HachfeldMatthias L. Schmid, Pietro Antonini, Peter Pongratz, Peter Kern, José Saraiva Da Cunha, Antoni Soriano-Arandes, Mirjam Schunk, Norbert Suttorp, Christoph Hatz, Thomas Zoller

Research output: Contribution to journalArticlepeer-review

Abstract

Intravenous artesunate improves survival in severe malaria, but clinical trial data from nonendemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs quinine treatment. Artesunate reduced parasite clearance time and duration of intensive care unit and hospital treatment in European patients with imported severe malaria.

Original languageEnglish
Pages (from-to)1441-1444
Number of pages4
JournalClinical Infectious Diseases
Volume61
Issue number9
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • artesunate
  • clinical study
  • Plasmodium falciparum
  • quinine
  • severe malaria

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study'. Together they form a unique fingerprint.

Cite this